X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALKEM LABORATORIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALKEM LABORATORIES AUROBINDO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 15.6 - - View Chart
P/BV x 4.0 7.5 53.3% View Chart
Dividend Yield % 0.4 0.6 67.6%  

Financials

 AUROBINDO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
ALKEM LABORATORIES
Mar-16
AUROBINDO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8951,589 56.3%   
Low Rs6221,232 50.5%   
Sales per share (Unadj.) Rs254.6417.5 61.0%  
Earnings per share (Unadj.) Rs39.356.3 69.8%  
Cash flow per share (Unadj.) Rs46.664.7 72.0%  
Dividends per share (Unadj.) Rs2.5012.70 19.7%  
Dividend yield (eoy) %0.30.9 36.6%  
Book value per share (Unadj.) Rs160.0292.9 54.6%  
Shares outstanding (eoy) m585.88119.57 490.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 88.2%   
Avg P/E ratio x19.325.1 77.1%  
P/CF ratio (eoy) x16.321.8 74.7%  
Price / Book Value ratio x4.74.8 98.5%  
Dividend payout %6.422.6 28.2%   
Avg Mkt Cap Rs m444,390168,653 263.5%   
No. of employees `00014.0NA-   
Total wages/salary Rs m17,6789,171 192.7%   
Avg. sales/employee Rs Th10,667.8NM-  
Avg. wages/employee Rs Th1,264.3NM-  
Avg. net profit/employee Rs Th1,645.8NM-  
INCOME DATA
Net Sales Rs m149,15749,915 298.8%  
Other income Rs m1,1591,645 70.4%   
Total revenues Rs m150,31651,561 291.5%   
Gross profit Rs m34,3438,482 404.9%  
Depreciation Rs m4,2761,006 425.2%   
Interest Rs m667671 99.5%   
Profit before tax Rs m30,5588,451 361.6%   
Minority Interest Rs m50-114 -44.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,606 473.0%   
Profit after tax Rs m23,0126,731 341.9%  
Gross profit margin %23.017.0 135.5%  
Effective tax rate %24.919.0 130.8%   
Net profit margin %15.413.5 114.4%  
BALANCE SHEET DATA
Current assets Rs m92,06227,062 340.2%   
Current liabilities Rs m66,22315,324 432.2%   
Net working cap to sales %17.323.5 73.7%  
Current ratio x1.41.8 78.7%  
Inventory Days Days10667 159.4%  
Debtors Days Days6841 163.9%  
Net fixed assets Rs m62,91912,610 499.0%   
Share capital Rs m586239 245.0%   
"Free" reserves Rs m93,13334,490 270.0%   
Net worth Rs m93,71935,027 267.6%   
Long term debt Rs m1,8141,212 149.7%   
Total assets Rs m162,49454,387 298.8%  
Interest coverage x46.813.6 344.1%   
Debt to equity ratio x00 56.0%  
Sales to assets ratio x0.90.9 100.0%   
Return on assets %14.613.6 107.1%  
Return on equity %24.619.2 127.8%  
Return on capital %32.724.9 131.7%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m75,8386,563 1,155.5%   
Fx outflow Rs m30,2243,012 1,003.6%   
Net fx Rs m45,6133,552 1,284.3%   
CASH FLOW
From Operations Rs m32,7867,259 451.7%  
From Investments Rs m-17,8701,864 -958.6%  
From Financial Activity Rs m-19,153-9,273 206.5%  
Net Cashflow Rs m-4,239-150 2,825.8%  

Share Holding

Indian Promoters % 54.1 66.9 80.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 33.1 24.0%  
FIIs % 27.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 0.0 -  
Shareholders   69,601 68,381 101.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS